April 18, 2022 11:24 AM EDT
Pharma
Law

Bris­tol My­ers inks $11M deal to set­tle an­ti­com­pet­i­tive claims in HIV suit

Nicole DeFeudis

Editor

Three years ago, AIDS ac­tivists filed a law­suit ac­cus­ing Bris­tol My­ers Squibb, Gilead, and John­son & John­son of schem­ing to block gener­ic HIV med­i­cines from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio sticks to script for AT­TR-CM as Al­ny­lam cleans up ‘ty­po’ sna­fu

Roche's Spark los­es CEO to RNA up­start; Ex-El­e­va­tion On­col­o­gy chief takes over at Af­fimed

Ex­clu­sive: Lil­ly-backed Or­so­Bio rais­es $67M for slate of obe­si­ty drugs as com­bi­na­tions take root

GSK’s Nu­cala cuts ex­ac­er­ba­tions in Phase 3 COPD tri­al, but num­bers re­main un­der wraps

Bicara, Zenas out­line plans for $180M IPOs amid re­stored op­ti­mism for biotech de­buts

sponsored

How to se­cure full en­roll­ment and a 30x ROI: A con­ver­sa­tion with the CEO of the bou­tique en­roll­ment agency do­ing just ...

A service from the Financial Times